Clinical Trial Update: Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluated ABT-384 for efficacy and safety in patients with mild-to-moderate Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ABT-384 (ABT-384)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED